Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Purpose: To provide patients and clinicians more accurate estimates of comorbidity-specific survival stratified by patient age, tumor stage, and tumor grade. Patients and Methods: We conducted a 10-year competing risk analysis of 19,639 men 66 years of age and older identified by the Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare program files. All men were diagnosed with localized prostate cancer and received no surgery or radiation within 180 days of diagnosis. The analysis was stratified by tumor grade and stage and by age and comorbidity at diagnosis classified using the Charlson comorbidity index. Underlying causes of death were obtained from SEER. Results: During the first 10 years after diagnosis, men with moderately and poorly differentiated prostate cancer were more likely to die from causes other than their disease. Depending on patient age, Gleason score, and number of comorbidities present at diagnosis, 5-year overall mortality rates for men with stage T1c disease ranged from 11.7% (95% CI, 10.2% to 13.1%) to 65.7% (95% CI, 55.9% to 70.1%), and prostate cancer–specific mortality rates ranged from 1.1% (95% CI, 0.0% to 2.7%) to 16.3% (95% CI, 13.8% to 19.4%). Ten-year overall mortality rates ranged from 28.8% (95% CI, 25.3% to 32.6%) to 94.3% (95% CI, 87.4% to 100%), and prostate cancer–specific mortality rates ranged from 2.0% (95% CI, 0.0% to 5.3%) to 27.5% (95% CI, 21.5% to 36.5%). Conclusion: Patients and clinicians should consider using comorbidity-specific data to estimate the threat posed by newly diagnosed localized prostate cancer and the threat posed by competing medical hazards.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
An Introduction to the Bootstrap.
Buckland, S. T., Efron, B., & Tibshirani, R. J. (1994) · Biometrics · doi:10.2307/2532810 · Cited by 3,103
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M., & Geskus, R. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,440
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Survival Analysis Part I: Basic concepts and first analyses
Clark, T. G., Bradburn, M. J., Love, S. B., & Altman, D. G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601118 · Cited by 1,030
EAU Guidelines on Prostate Cancer
Aus, G., Abbou, C. C., Bolla, M., Heidenreich, A., Schmid, H.-P., van Poppel, H., Wolff, J., & Zattoni, F. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.001 · Cited by 579
Klabunde, C. N., Legler, J. M., Warren, J. L., Baldwin, L.-M., & Schrag, D. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.03.011 · Cited by 514
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-3-200808050-00008 · Cited by 505
Outcomes of Localized Prostate Cancer Following Conservative Management
Lu-Yao, G. L. (2009) · JAMA · doi:10.1001/jama.2009.1348 · Cited by 430
Self-citationProstate Cancer and the Will Rogers Phenomenon
Albertsen, P. C., Hanley, J. A., Barrows, G. H., Penson, D. F., Kowalczyk, P. D. H., Sanders, M. M., & Fine, J. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji248 · Cited by 382
Self-citationHazard Rate Estimation under Random Censoring with Varying Kernels and Bandwidths
Muller, H.-G., & Wang, J.-L. (1994) · Biometrics · doi:10.2307/2533197 · Cited by 340
The Impact of Co-morbidity on Life Expectancy Among Men with Localized Prostate Cancer
Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F., & Fine, J. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65964-0 · Cited by 238
Self-citationWalz, J., Gallina, A., Saad, F., Montorsi, F., Perrotte, P., Shariat, S. F., Jeldres, C., Graefen, M., Bénard, F., McCormack, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3820 · Cited by 220
Katz, M. D. (2008) · Yearbook of Urology · doi:10.1016/s0084-4071(08)79028-6 · Cited by 171
TEWARI, A., JOHNSON, C. C., DIVINE, G., CRAWFORD, E. D., GAMITO, E. J., DEMERS, R., & MENON, M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000117975.40782.95 · Cited by 164
Update: NCCN prostate cancer Clinical Practice Guidelines.
Scardino, P. T. (2005) · PubMed · Cited by 136
Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid?
Penson, D. F., Albertsen, P. C., Nelson, P. S., Barry, M., & Stanford, J. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.23.1822 · Cited by 129
Self-citationAlbertsen, P. C., WALTERS, S., & Hanley, J. A. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67915-3 · Cited by 104
Self-citationRe: Mortality Results from a Randomized Prostate-Cancer Screening Trial
Roobol, M. J. (2009) · European Urology · doi:10.1016/j.eururo.2009.03.085 · Cited by 100
The assessment of patient life‐expectancy: how accurate are urologists and oncologists?
Wilson, J. R. M., Clarke, M., Ewings, P., Graham, J. D., & MacDonagh, R. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05403.x · Cited by 73
Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status
Mohan, R., Beydoun, H. A., Barnes-Ely, M. L., Lee, L., Davis, J. W., Lance, R., & Schellhammer, P. F. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.03.080200 · Cited by 32
Cited by
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Self-citationEdwards, B. K., Noone, A., Mariotto, A. B., Simard, E. P., Boscoe, F. P., Henley, S. J., Jemal, A., Cho, H., Anderson, R. N., Kohler, B. A., et al. (2014) · Cancer · doi:10.1002/cncr.28509 · Cited by 1,210
Metadata
- Authors
- Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., Li, H., & Lu-Yao, G. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-01
- Volume
- 29
- Issue
- 10
- Pages
- 1335-1341
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163098725
- Cited by
- 312
- References
- 30
- FWCI
- 28.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.